- Home
- BNR vs SABS Comparison
BNR vs SABS Comparison
Compare BNR & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNR
- SABS
- Stock Information
- Founded
- BNR 2014
- SABS 2014
- Country
- BNR China
- SABS United States
- Employees
- BNR N/A
- SABS N/A
- Industry
- BNR Medical Specialities
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- BNR Health Care
- SABS Health Care
- Exchange
- BNR Nasdaq
- SABS Nasdaq
- Market Cap
- BNR 38.3M
- SABS 31.2M
- IPO Year
- BNR 2020
- SABS N/A
- Fundamental
- Price
- BNR $12.25
- SABS $3.06
- Analyst Decision
- BNR
- SABS Strong Buy
- Analyst Count
- BNR 0
- SABS 3
- Target Price
- BNR N/A
- SABS $9.00
- AVG Volume (30 Days)
- BNR 33.9K
- SABS 261.4K
- Earning Date
- BNR 12-02-2025
- SABS 11-06-2025
- Dividend Yield
- BNR N/A
- SABS N/A
- EPS Growth
- BNR N/A
- SABS N/A
- EPS
- BNR N/A
- SABS N/A
- Revenue
- BNR $74,862,782.00
- SABS $114,698.00
- Revenue This Year
- BNR $136.32
- SABS N/A
- Revenue Next Year
- BNR N/A
- SABS N/A
- P/E Ratio
- BNR N/A
- SABS N/A
- Revenue Growth
- BNR 5.20
- SABS N/A
- 52 Week Low
- BNR $2.18
- SABS $1.00
- 52 Week High
- BNR $13.89
- SABS $6.60
- Technical
- Relative Strength Index (RSI)
- BNR 60.87
- SABS 59.76
- Support Level
- BNR $11.31
- SABS $2.93
- Resistance Level
- BNR $12.71
- SABS $3.34
- Average True Range (ATR)
- BNR 1.04
- SABS 0.23
- MACD
- BNR 0.09
- SABS 0.01
- Stochastic Oscillator
- BNR 72.11
- SABS 61.69
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.